Helix BioPharma has established a subsidiary in Poland, Helix Polska, to facilitate and support ongoing clinical oncology research at leading institutions in the country. The company’s relationship with Poland commenced in 2005 when Polish investors first became shareholders of Helix.
The firm’s product development initiatives are primarily focused on its L-DOS47 and Topical Interferon Alpha-2b drug candidates. Currently, Helix is conducting a Phase I/II clinical study in Poland with L-DOS47 in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous stage non-small-cell lung cancer. Enrollment for the fourth cohort of the trial was initiated in May and it is being conducted at four Polish centers: the Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, the Military Medical Institute, the National Tuberculosis and Lung Diseases Research Institute, and the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock.